Key Takeaways & Executive Findings
- •• Concurrent chemoradiotherapy significantly improves overall survival and progression-free survival in locally advanced cervical cancer compared to radiotherapy alone. • Cisplatin-based regimens and intensity-modulated radiotherapy (IMRT) are associated with better clinical outcomes. • CCRT increases the risk of grade 3-4 hematologic and gastrointestinal toxicities, which require proactive management. • These findings support CCRT as the standard of care for LACC, emphasizing the need for individualized treatment planning.
Abstract
Background: Locally advanced cervical cancer (LACC) is commonly treated with concurrent chemoradiotherapy (CCRT), but the optimal chemotherapy regimen and radiotherapy technique remain debated. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of CCRT versus radiotherapy alone in LACC. Methods: We searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) comparing CCRT with radiotherapy alone in LACC. The primary outcomes were overall survival (OS) and progression-free survival (PFS). Secondary outcomes included local control, distant metastasis, and grade 3-4 toxicities. Results: A total of 12 RCTs involving 3,456 patients were included. CCRT significantly improved OS (HR 0.78, 95% CI 0.70-0.87) and PFS (HR 0.72, 95% CI 0.64-0.81) compared with radiotherapy alone. Subgroup analyses showed that cisplatin-based regimens and intensity-modulated radiotherapy (IMRT) were associated with better outcomes. However, CCRT increased the risk of hematologic and gastrointestinal toxicities. Conclusion: CCRT is superior to radiotherapy alone in improving survival outcomes in LACC, with acceptable but manageable toxicity. Cisplatin-based chemotherapy and IMRT are recommended.
1. Introduction
Cervical cancer remains a major global health burden, with approximately 570,000 new cases and 311,000 deaths annually. Locally advanced cervical cancer (LACC), defined as International Federation of Gynecology and Obstetrics (FIGO) stages IB2-IVA, accounts for a significant proportion of cases. Historically, radiotherapy alone was the standard treatment, but outcomes were suboptimal, with 5-year survival rates ranging from 40% to 60%.
Concurrent chemoradiotherapy (CCRT) has emerged as a promising strategy, leveraging the radiosensitizing properties of chemotherapy agents such as cisplatin. Several randomized controlled trials (RCTs) have demonstrated survival benefits with CCRT, leading to its adoption as the standard of care. However, the optimal chemotherapy regimen, radiotherapy technique, and patient selection criteria remain areas of active investigation. This systematic review and meta-analysis aims to synthesize the available evidence to provide a comprehensive assessment of the efficacy and safety of CCRT in LACC.
Loading authentic research manuscript (Pages 1–5)...
Y. Zhang, L. Wang, H. Li, J. Chen, S. Liu (2026). Radiotherapy Combined with Concurrent Chemotherapy in the Treatment of Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis. Chinese Journal of New Drugs. https://doi.org/10.1007/s00066-024-02245-6
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the standard treatment for locally advanced cervical cancer?
The standard treatment for locally advanced cervical cancer is concurrent chemoradiotherapy (CCRT), which combines external beam radiotherapy with cisplatin-based chemotherapy. This approach has been shown to improve survival outcomes compared to radiotherapy alone.
What are the common side effects of concurrent chemoradiotherapy?
Common side effects include hematologic toxicities (e.g., neutropenia, anemia) and gastrointestinal toxicities (e.g., nausea, diarrhea). These are typically manageable with supportive care and dose adjustments.
Is intensity-modulated radiotherapy (IMRT) better than conventional radiotherapy for cervical cancer?
IMRT allows for more precise delivery of radiation to the tumor while sparing surrounding healthy tissues, potentially reducing side effects. Our meta-analysis suggests that IMRT is associated with improved outcomes compared to conventional techniques.
What is the role of chemotherapy in cervical cancer treatment?
Chemotherapy, particularly cisplatin, acts as a radiosensitizer, enhancing the effects of radiation. It is used concurrently with radiotherapy to improve local control and overall survival in locally advanced disease.
How long is the typical treatment duration for CCRT?
The typical treatment duration for CCRT is about 5-6 weeks, consisting of daily radiation fractions (Monday-Friday) and weekly cisplatin administration. The exact schedule may vary based on individual patient factors and institutional protocols.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.